NGS Banner

Graham Speight, Carolin Müller, James Reid, Lynne Edhouse, Jolyon Holdstock, Lyudmila Georgieva



The capture and molecular analysis of cell-free DNA (cfDNA) released from cells under certain pathological conditions, including cancer, provides a non-invasive alternative to currently used practices via use of liquid biopsy samples.

The rapid development of next-generation sequencing (NGS) technologies in recent years, has led to a significant reduction in sequencing cost with improved accuracy.

In liquid biopsy research, NGS can be applied to sequence circulating tumour DNA (ctDNA; DNA fragments released by tumour cells). As such, NGS could provide molecular characterisation of tumour-specific genomic alterations in ctDNA, allowing for non-invasive and real-time monitoring of disease development.

The aim of this study is to evaluate a modified version of the OGT™ Universal NGS Workflow Solution in conjunction with a custom SureSeq™ targeted panel for use with cfDNA.

Register with us to read the full article

Once you have registered with us for free you will be able to read all our supportive literature, video tutorials and webinars.

You might also be interested in

Simultaneous detection of genetic and copy-number variations in BRCA1/2 genes

  • Resource type: Scientific poster
  • Application: Solid tumour

Assessment of Interpret software on low-frequency variants using reference standards

  • Resource type: Scientific poster
  • Application: Haematology, Solid tumour
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter